TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00261170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: 150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
Study: NCT01802554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleasant Events Program (PEP)
Description: Behavioral Activation Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support (IS)
Description: Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
Study: NCT02723292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Study: NCT02204826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng (KRG)
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Korean Red Ginseng (KRG)
Description: The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Description: Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Varicocelectomy
Description: Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
Study: NCT01895452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Low Dose
Description: Intramuscular injection, given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, High Dose
Description: Intramuscular injection, given monthly
Study: NCT02260648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study: NCT04221893

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo radiation therapy
Study: NCT01604460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation with torso plastic bag
Description: Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Resuscitation-no plastic bag
Description: Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
Study: NCT00951392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: euglycemic hyperinsulinemic clamp
Description: Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: euglycemic hyperinsulinemic clamp
Description: Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: indirect calorimetry
Description: energy expenditure measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: indirect calorimetry
Description: energy expenditure measurement
Study: NCT02382354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel
Description: I-gel insertion was inserted 5 min after anesthesia induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask airway
Description: laryngeal mask airway insertion was inserted 5 min after anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
Study: NCT03722979

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac surgery
Description: The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
Study: NCT02260648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00902330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: energy-based therapy
Description: Given once a day for 18 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Given once a day for 18 weeks
Study: NCT03560492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: 5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture garment
Description: Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
Study: NCT04278248

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine
Description: 1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine
Description: 1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
Study: NCT01485848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP-100
Description: Pharmaceutical form:Solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study: NCT04025892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily weighing
Description: Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
Study: NCT03467516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
Study: NCT01059747

Intervention type: OTHER
Intervention: no intervention applied
Description: no intervention applied
Study: NCT00691392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Methylcellulose - Placebo
Description: The placebo will be over-encapsulated microcrystalline methylcellulose
Study: NCT03446430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PWV measurement by LDV
Description: PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
Study: NCT01529229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine + Betamethasone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine + Prednisolone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Study: NCT01977378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained-Release Desvenlafaxine Hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-Release Venlafaxine Hydrochloride
Study: NCT03709524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq + fiberoptic
Description: video laryngoscope with a monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq + fiberoptic
Description: video laryngoscope with a monitor
Study: NCT03960840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapcabtagene autoleucel single agent
Description: Single infusion of rapcabtagene autoleucel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapcabtagene autoleucel single agent
Description: Single infusion of rapcabtagene autoleucel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapcabtagene autoleucel single agent
Description: Single infusion of rapcabtagene autoleucel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapcabtagene autoleucel single agent
Description: Single infusion of rapcabtagene autoleucel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Tablets or capsules for oral daily use
Study: NCT03534388

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Hypochlorite Cleanser
Description: Cleansing with CLn BodyWash
Study: NCT01900886

Intervention type: OTHER
Intervention: Peginterferon alfa-2a
Description: Treatment as usual clinical practice

Intervention type: DRUG
Intervention: Ribavirin
Description: Treatment as usual clinical practice
Study: NCT03593148

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle
Description: Lifestyle treatment
Study: NCT04596722

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomella
Description: Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts
Study: NCT03709524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: video laryngoscope with a monitor
Study: NCT03092180

Intervention type: DRUG
Intervention: Intravenous Infusion
Description: Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
Study: NCT03709524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: video laryngoscope with a monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal Airtraq + styletted tube
Description: video laryngoscope with a monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal Airtraq + styletted tube
Description: video laryngoscope with a monitor
Study: NCT02158702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide and Dexamethasone
Description: Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
Study: NCT01830296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+morphine
Description: Morphine, Remifentanil+Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+morphine
Description: Morphine, Remifentanil+Morphine
Study: NCT03543358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rovalpituzumab tesirine
Description: Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rovalpituzumab tesirine
Description: Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
Study: NCT00698061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 3-dose primary vaccination and booster vaccination by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose primary vaccination and booster vaccination by intramuscular injection
Study: NCT03519516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-174
Description: Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sophixín Ofteno®
Description: * Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Study: NCT04427436

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT01884168

Intervention type: BIOLOGICAL
Intervention: Dc-CIK immunotherapy
Description: The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
Study: NCT02518308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
Study: NCT02387372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam - Multiple Doses
Description: 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam - Single Dose
Description: Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
Study: NCT01925859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
Description: erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
Study: NCT01522040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Continuous magnesium drip, titrated to effect until patient's symptoms improve

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simple saline drip, without active drug
Study: NCT03894774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive in-patient psychotherapy treatment
Description: Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
Study: NCT02600052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
Study: NCT03894774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
Study: NCT03311399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSI Screening Tool used in home visits by CHWs
Description: Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
Study: NCT02600052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Description: AEROBIC TRAINING

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: AEROBIC TRAINING
Study: NCT03511651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Two PEEP levels will be used during mechanical ventilation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP
Description: Two PEEP levels will be used during mechanical ventilation.
Study: NCT03311399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSI Screening Tool used via phone call follow-up
Description: Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
Study: NCT01026389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadovist
Description: Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
Study: NCT04094766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
Study: NCT03503214

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination of non-carbonic buffer power
Description: In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
Study: NCT03883529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Writing about and reviewing birth experience
Description: Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
Study: NCT00875160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT2101
Description: 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
Study: NCT04450199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: Vitamin D tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over encapsulated sugar pills
Study: NCT01013246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-hour video game play
Description: FIFA 2009, a football video game played on Xbox 360